chufangao/CTO huggingface dataset:
Clinical trial NCT04534114: Factor XI LICA to Reduce Events Such as Heart Attack and Stroke in Patients Whose Kidneys Are no Longer Able to Work as They Should and Require Treatment to Filter Wastes From the Blood: Focus is on the Safety of BAY2976217 and the Way the Body Absorbs, Distributes and Removes the Study Drug
Official title: Factor XI LICA to Reduce Thrombotic Events in End-Stage Renal Disease Patients on Hemodialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of BAY 2976217
Acronym: RE-THINc ESRD
Sponsor: Bayer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 307.0 (ACTUAL)
Number of arms: 4.0
Start date: 2020-09-04
Primary completion date: 2022-01-24
Completion date: 2022-05-12
Plan to share individual participant data: NO
IPD sharing description: There are no current plans to share data. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.
Clinical trial NCT05093387: SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer
Official title: A Pilot Study of SGT-53 With Carboplatin and Pembrolizumab in Metastatic Triple Negative Inflammatory Breast Cancer
Sponsor: Northwestern University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: funding issues and pharmacy preparation for the drug
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-11-10
Primary completion date: 2022-11-10
Completion date: 2022-11-10
Clinical trial NCT04190628: Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors
Official title: A Phase I, First-In-Human, Multicenter, Open-Label Dose Escalation and Dose Expansion Study of ABM-1310, as a Monotherapy and a Combination Therapy, Administered Orally in Adult Patients With Advanced Solid Tumors Harboring BRAF Mutations
Sponsor: ABM Therapeutics Corporation (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Not related to safety concerns or lack of efficacy
Enrollment: 53.0 (ACTUAL)
Number of arms: 6.0
Start date: 2020-06-16
Primary completion date: 2024-04-05
Completion date: 2024-04-05
Plan to share individual participant data: NO
Clinical trial NCT03843541: A Clinical Trial to Compare the Efficacy and Safety of 1-week Treatment of Intravenous N-acetylcysteine (NAC) 600 mg Twice Daily, Ambroxol Hydrochloride 30 mg Twice Daily and Placebo as Expectorant Therapies in Adult Chinese Patients With Respiratory Tract Diseases and Abnormal Mucus Secretions
Official title: A Phase III, Multi-centre, Randomized, Rater- and Patient-blind, Placebo- and Active-controlled, Parallel Group Clinical Trial to Compare the Efficacy and Safety of 1-week Treatment of Intravenous N-acetylcysteine (NAC) 600 mg Twice Daily (Active Test Treatment), Ambroxol Hydrochloride 30 mg Twice Daily (Active Control Treatment) and Placebo as Expectorant Therapies in Adult Chinese Patients With Respiratory Tract Diseases and Abnormal Mucus Secretions
Sponsor: Zambon SpA (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 333.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-06-25
Primary completion date: 2021-01-23
Completion date: 2021-02-05
Baseline population: mITT population - The Modified ITT (mITT) Population comprised all participants in the ITT population who received at least 1 dose or partial dose of the Investigational Medicinal Product (IMP).
Clinical trial NCT02301156: Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)
Official title: A Phase 3, Randomized, Study to Assess the Efficacy and Safety of Ublituximab in Combination With Ibrutinib Compared to Ibrutinib Alone, in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)
Acronym: GENUINE
Sponsor: TG Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 126.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-01-27
Primary completion date: 2020-04-01
Completion date: 2020-04-01
Baseline population: ITT Population included all randomized participants.
Plan to share individual participant data: NO
IPD sharing description: TG Therapeutics does not currently plan to share IPD.
Clinical trial NCT04835714: A Study to Find a Safe and Effective Dose of BI 1701963 Alone and in Combination With BI 3011441 in Patients With Advanced Cancer and a Certain Mutation (Kirsten Rat Sarcoma Viral Oncogene Homologue [KRAS])
Official title: A Phase I Open-label Dose Escalation Trial of BI 1701963 as Monotherapy and in Combination With BI 3011441 in Patients With KRAS Mutated Advanced or Metastatic Solid Tumours
Sponsor: Boehringer Ingelheim (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Sponsor decision
Enrollment: 8.0 (ACTUAL)
Number of arms: 4.0
Start date: 2021-04-20
Primary completion date: 2022-01-18
Completion date: 2022-01-18
Plan to share individual participant data: NO
IPD sharing description: Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions:~1. studies in products where Boehringer Ingelheim is not the license holder;~2. studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials;~3. studies conducted in a single center or targeting rare diseases (because of limitations with anonymization).~For more details refer to: https://www.mystudywindow.com/msw/datasharing
Clinical trial NCT05724628: Non-operative vs. Operative Management of Acute Appendicitis in Vulnerable Patient Populations
Official title: A Pilot Randomized Trial of Non-operative Versus Operative Management of Acute Appendicitis in Vulnerable Patient Populations
Sponsor: University of Texas Southwestern Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Project did not receive final IRB approvals. PI decided to withdrawn research study.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-10-31
Primary completion date: 2023-11-30
Completion date: 2023-11-30
Plan to share individual participant data: NO
Clinical trial NCT03483961: Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults
Official title: A Phase 2 Parallel-Group, Randomized, Double-Blind Study to Assess the Safety and Immunogenicity of PXVX0317 (Chikungunya Virus Virus-Like Particle Vaccine [CHIKV-VLP], Unadjuvanted or Alum-adjuvanted)
Sponsor: Bavarian Nordic (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 445.0 (ACTUAL)
Number of arms: 10.0
Start date: 2018-04-18
Primary completion date: 2020-09-14
Completion date: 2020-09-21
Baseline population: Randomized participants.
Plan to share individual participant data: NO
Clinical trial NCT03369184: Elective Percutaneous Coronary Intervention With or Without Supplemental OXYgen
Official title: Elective Percutaneous Coronary Intervention With or Without Supplemental OXYgen and Evaluation of Effects on Coronary Microcirculation Using the Index of Microcirculatory Resistance
Acronym: EPOXY-IMR
Sponsor: Karolinska Institutet (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Slow recruitment
Enrollment: 65.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-01-01
Primary completion date: 2019-05-01
Completion date: 2020-08-01
Clinical trial NCT04589832: Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma
Official title: Phase 1B/2 Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma
Sponsor: Hoosier Cancer Research Network (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: This study required dose reductions to the lower dose level (Dose level -1). But this dose level (Dose level -1) was not further explored because of lack of funding.
Enrollment: 6.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-01-11
Primary completion date: 2022-03-22
Completion date: 2022-06-24
Plan to share individual participant data: NO
Clinical trial NCT05135546: Inhaled Recombinant Non-immunogenic Staphylokinase vs Placebo in Patients With COVID-19 - FORRIF Trial
Official title: Inhaled Recombinant Non-immunogenic Staphylokinase vs Placebo in Patients With COVID-19 - FORRIF Trial
Acronym: FORRIF
Sponsor: Supergene, LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: No patients
Enrollment: 4.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-12-27
Primary completion date: 2023-02-01
Completion date: 2023-05-31
Plan to share individual participant data: NO
Clinical trial NCT03400176: VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib
Official title: Phase Ib Open-label Study of VAY736 and Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL) on Ibrutinib Therapy
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Business reasons
Enrollment: 39.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-04-09
Primary completion date: 2023-09-29
Completion date: 2023-09-29
Plan to share individual participant data: NO
Clinical trial NCT03422523: Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose Therapy
Official title: A Phase II Study of Atezolizumab With Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Who Are Not Candidates for High-dose Therapy
Acronym: ARGO
Sponsor: University Hospital Southampton NHS Foundation Trust (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Failure to reach pre-specified futility boundary
Enrollment: 53.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-05-09
Primary completion date: 2021-01-31
Completion date: 2021-11-18
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03759041: A Study to Assess Efficacy and Safety of SER-287 in Adults With Active Mild-to-Moderate Ulcerative Colitis
Official title: ECO-RESET: A Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter Study to Assess Efficacy and Safety of SER-287 in Adults With Active Mild-to-Moderate Ulcerative Colitis
Acronym: ECO-RESET
Sponsor: Seres Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Due to the lack of a clinical efficacy signal in the induction treatment phase, Seres closed the dosing phases of open label and maintenance portions of the study. Patients who had received prior doses were followed for safety data.
Enrollment: 203.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-12-19
Primary completion date: 2021-05-28
Completion date: 2021-10-13
Baseline population: Intent-to-treat
Clinical trial NCT04977336: A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy
Official title: A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging, Study Evaluating the Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy
Sponsor: Vertex Pharmaceuticals Incorporated (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 274.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-07-19
Primary completion date: 2022-02-17
Completion date: 2022-03-04
Plan to share individual participant data: NO
IPD sharing description: Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing
Clinical trial NCT05061277: Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Recifercept in Healthy Chinese Participants
Official title: A PHASE 1, OPEN-LABEL, SINGLE SUBCUTANEOUS DOSE STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF LYOPHILIZED FORMULATION OF RECIFERCEPT IN HEALTHY CHINESE PARTICIPANTS
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Pfizer has decided to cancel study C4181006 due to strategic considerations. This decision is not due to any specific reasons or requests from any regulatory authorities. No participants have been enrolled in this study.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2023-10-25
Primary completion date: 2023-12-12
Completion date: 2024-06-16
Plan to share individual participant data: NO
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT06329687: A Study Evaluating the Safety of the Nasal Pump
Official title: A Phase 4, Single-Center, Open-Label Study Evaluating the Safety of the Tyrvaya Nasal Pump
Sponsor: Oyster Point Pharma, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Internal strategy change. Not related to safety concerns.
Enrollment: 5.0 (ACTUAL)
Number of arms: 1.0
Start date: 2024-02-21
Primary completion date: 2024-02-28
Completion date: 2024-02-28
Clinical trial NCT04810611: Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS
Official title: A Phase Ib, Multicenter, Open-label Platform Study of Select Drug Combinations in Adult Patients With Lower Risk (Very Low, Low, or Intermediate Risk) Myelodysplastic Syndrome
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Business reasons
Enrollment: 33.0 (ACTUAL)
Number of arms: 5.0
Start date: 2021-06-18
Primary completion date: 2024-04-19
Completion date: 2024-04-19
Plan to share individual participant data: NO
Clinical trial NCT02757391: CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors
Official title: Pilot Study of Feasibility and Safety of Personalized Autologous CD8+ T Cell Therapy Plus Anti-PD1 Antibody in Advanced Solid Malignancies
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention.
Enrollment: 1.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-08-09
Primary completion date: 2020-10-02
Completion date: 2020-10-02
Clinical trial NCT04149574: A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)
Official title: A Phase 3, Randomized, Double-blind Trial of Nivolumab in Combination With Intravesical BCG Versus Standard of Care BCG Alone in Participants With High-risk Non-muscle Invasive Bladder Cancer That Is Persistent or Recurrent After Treatment With BCG
Acronym: CheckMate 7G8
Sponsor: Bristol-Myers Squibb (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Insufficient enrollment, inability to meet protocol objectives, and slow accrual.
Enrollment: 13.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-01-15
Primary completion date: 2023-10-31
Completion date: 2023-10-31
Clinical trial NCT04197869: Does a Preoperative Bowel Regimen Change Time to First Bowel Movement After Robotic Sacral Colpopexy
Official title: Does a Preoperative Bowel Regimen Change Time to First Bowel Movement After Robotic Sacral Colpopexy: A Randomized Controlled Trial
Sponsor: Northwell Health (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 48.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-12-09
Primary completion date: 2023-06-21
Completion date: 2023-06-21
Plan to share individual participant data: UNDECIDED
Clinical trial NCT05052554: Study With QR-504a to Evaluate Safety, Tolerability & Corneal Endothelium Molecular Biomarker(s) in Subjects With FECD3
Official title: Open-Label, Single-Dose, Exploratory Study With QR-504a to Evaluate Safety, Tolerability, and Corneal Endothelium Molecular Biomarker(s) in Subjects With Fuchs Endothelial Corneal Dystrophy With Trinucleotide Repeat Expansion in the TCF4 Gene (FECD3)
Acronym: Fuchs Focus
Sponsor: ProQR Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: No patients
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-08-10
Primary completion date: 2022-04-12
Completion date: 2022-04-12
Plan to share individual participant data: NO
Clinical trial NCT04448132: Evaluation of Persistence of Immunity in 4-year-old Children Previously Immunised With IPV-Al AJV (Picovax®)
Official title: Evaluation of the Persistence of the Immunity in 4-year-old Children Previously Immunised With an Adjuvanted Reduced Dose Inactivated Polio Vaccine, IPV-Al AJV (Picovax®) by Measuring the Response to an Additional Dose of IPV-Al AJV
Sponsor: AJ Vaccines A/S (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 163.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-11-20
Primary completion date: 2021-05-03
Completion date: 2021-05-03
Plan to share individual participant data: NO
Clinical trial NCT04585776: A Study of LY900014 and Insulin Degludec in Participants With Type 1 Diabetes
Official title: An Exploratory Study Assessing Time in Target Glucose Range Using a New Titration Scheme of LY900014 and Insulin Degludec in Patients With Type 1 Diabetes
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 31.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-10-30
Primary completion date: 2021-05-27
Completion date: 2021-05-27
Baseline population: All enrolled participants.
Plan to share individual participant data: YES
IPD sharing description: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
IPD access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Clinical trial NCT03852628: Kappa Opioid Receptor Antagonism for the Tx of AUD and Comorbid PTSD
Official title: Kappa Opioid Receptor Antagonism for the Treatment of Alcohol Use Disorder (AUD) and Comorbid Post-Traumatic Stress Disorder (PTSD)
Sponsor: Pharmacotherapies for Alcohol and Substance Use Disorders Alliance (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Futility analysis
Enrollment: 69.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-05-20
Primary completion date: 2022-05-02
Completion date: 2023-01-30
Limitations and caveats: There are no secondary outcome results to report as this study was closed for futility before enough data was collected to report secondary outcomes. .
Plan to share individual participant data: YES
IPD sharing description: CDMRP has a policy to share and make available to the public the results and accomplishments of the activities that it funds. The PASA consortium plans to share de-identified data after final publication in a government-supported data repository.
Clinical trial NCT05668936: A Thorough QTC Study to Assess the Effect of Cotadutide on Cardiac Repolarization in Healthy Participants
Official title: A Thorough QTc Evaluation of the Effect of Cotadutide on Cardiac Repolarization in Healthy Participants: A Randomized, Double-blind, Placebo-controlled, 3-arm Parallel Study With a Nested Crossover Design for Positive Control With Moxifloxacin Administration
Sponsor: AstraZeneca (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Discontinuing the development of cotadutide, a daily injectable GLP-1/glucagon co-agonist, is based on strategic pipeline considerations. The premature closure is not due to any newly observed safety signals or a change in the risk/benefit profile.
Enrollment: 31.0 (ACTUAL)
Number of arms: 3.0
Start date: 2023-01-03
Primary completion date: 2023-03-10
Completion date: 2023-03-10
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.~Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Clinical trial NCT03443622: Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors
Official title: Phase I Open-Label Dose-Escalating Study to Determine the Safety, Tolerability, Maximum Tolerated Dose, and Pharmacokinetics of SC-43 Oral Solution in Subjects With Refractory Solid Tumors
Sponsor: SupremeCure Pharma Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Another study has been started in other country.
Enrollment: 0.0 (ACTUAL)
Number of arms: 6.0
Start date: 2021-05-31
Primary completion date: 2022-12-31
Completion date: 2023-06-30
Clinical trial NCT03364764: Sirolimus Treatment for Refractory PRCA
Official title: Sirolimus Treatment for Refractory Pure Red Cell Aplasia, a Prospective Study
Sponsor: Peking Union Medical College Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 64.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-02-01
Primary completion date: 2019-02-01
Completion date: 2021-05-01
Plan to share individual participant data: NO